The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
Published in MedTech Strategist
Authors: Wendy Diller, Oded Ben-Joseph, Craig Steger, and Thomas Joyce
Abstract:
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
News
ProjectMedtech Podcast | Strategic Transactions in MedTech: Insights & Advice
Recent podcast conversation featuring Stanislav Glezer, Managing Director at Outcome Capital, on the ProjectMedtech Podcast, hosted by Duane Mancini.
Read MoreResources
Outcome Capital Life Science Market Pulse
Outcome Capital Life Science Market Pulse January 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
